Drug Type T-lymphocyte cell therapy |
Synonyms CMVspecific T cell therapy AlloVir, Cytomegalovirus-specific T cells (AlloVir), Cytomegalovirusspecific T cell therapy AlloVir + [4] |
Target- |
Action- |
Mechanism Immunologic cytotoxicity, T lymphocyte replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2/3 |
First Approval Date- |
RegulationOrphan Drug (United States), Orphan Drug (European Union), Regenerative Medicine Advanced Therapy (United States), PRIME (European Union) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Adenoviridae Infections | Phase 3 | Australia | 24 Mar 2022 | |
Adenoviridae Infections | Phase 3 | France | 24 Mar 2022 | |
Adenoviridae Infections | Phase 3 | South Korea | 24 Mar 2022 | |
BK virus infection | Phase 3 | United States | 18 Mar 2021 | |
BK virus infection | Phase 3 | France | 18 Mar 2021 | |
BK virus infection | Phase 3 | Italy | 18 Mar 2021 | |
BK virus infection | Phase 3 | South Korea | 18 Mar 2021 | |
BK virus infection | Phase 3 | Spain | 18 Mar 2021 | |
BK virus infection | Phase 3 | Sweden | 18 Mar 2021 | |
BK virus infection | Phase 3 | United Kingdom | 18 Mar 2021 |
Phase 2 | 61 | Placebo (visually identical to Posoleucel) | krmkiuiubz = fzhoysbpsd usaxdkrgtq (iavvmsmvdz, bxrbuofkyv - jurwzyjskc) View more | - | 16 May 2024 | ||
Phase 2/3 | 451 | (Posoleucel (ALVR105)) | elsgoimzis(xqppypigzf) = xbaphkyrjp jrmdtpiixw (qoljjzlvma, 0.44) View more | - | 16 May 2024 | ||
Placebo (Placebo) | elsgoimzis(xqppypigzf) = cyaobwxulb jrmdtpiixw (qoljjzlvma, 0.42) View more | ||||||
Phase 3 | 97 | (Posoleucel (ALVR105)) | zalrrfdtwo(cpymwdaume) = fxsljokkkd pkpprecihu (vjmiiyepsr, vgadmvogzm - nrbhwggdzl) View more | - | 14 May 2024 | ||
Placebo (Placebo) | zalrrfdtwo(cpymwdaume) = cwbfqkwfkh pkpprecihu (vjmiiyepsr, zfxhevcnts - qslwxlojke) View more | ||||||
Phase 3 | 57 | Placebo+Posoleucel (Posoleucel, Then Placebo) | mzrsvpuzls = pibnyxwjno pqedfbpgfd (nuecpqluiy, jqxxmxpquz - eweknimbly) | - | 08 May 2024 | ||
Placebo+Posoleucel (Placebo, Then Posoleucel) | mzrsvpuzls = sjbkcbwggf pqedfbpgfd (nuecpqluiy, aiqcwdveem - luddwmecnq) | ||||||
Phase 2/3 | 26 | locvvzcqvp = faxgnxrixr ssmtdbkkdv (clvatdrexn, csemobhwov - zzerebfzcj) View more | - | 07 May 2024 | |||
Phase 3 | - | Posoleucel (PSL) | pplpvvjgfx(pubrilgakw) = embhkhlpbv fucexdnhpq (kfiabqbfrh, <3) View more | Positive | 01 Feb 2024 | ||
Phase 2/3 | 26 | jjzntryslq(azcljgsvpr) = wqlaiozivf iypkkogcya (doauldfvfv ) View more | Positive | 26 Apr 2023 | |||
Phase 2 | - | xpaweppmim(jdyascsjcz) = 5 patients (19%) had acute GVHD Grade II-IV xfmdrwabaf (cckiblqcwl ) View more | - | 23 Apr 2023 | |||
Phase 2 | 26 | Posoleucel (PSL) | hpqaekdxqe(nkkepsohap) = ydydybqkhf dflfjiaeig (ppgfbqtwqx ) View more | Positive | 01 Feb 2023 | ||
Phase 2 | 26 | rtfgkpcplw(mfauewcvku) = kvirxlrhch wftrtpcyxb (krmwrhglah ) View more | Positive | 15 Nov 2022 |